Cyramza Injection

Ramucirumab
10mg/ml
ELI LILLY AND COMPANY
Pack size 50ml Glass Vial
Dispensing mode POM
Source USA
AgentPHARMATRADE
Retail Price 21477.50 AED

Available as:

Indications

Cyramza Injection is used for: For use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.

Adult Dose

Child Dose

Renal Dose

Administration

Contra Indications

Precautions

Pregnancy-Lactation

Interactions

Adverse Effects

Side effects of Ramucirumab :

Mechanism of Action

Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.

Note

Cyramza 10mg/ml Injection manufactured by ELI LILLY AND COMPANY. Its generic name is Ramucirumab. Cyramza is availble in United Arab Emirates. Farmaco UAE drug index information on Cyramza Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Ramucirumab :